

CANCER PREVENTION & RESEARCH Institute of Texas

CPRIT Legislative Appropriations Request for the 2024-25 Biennium Senate Finance Committee January 30, 2023

2024-25 LAR: Requested Items

- Base request of \$300 million in bond proceeds for each year of the biennium as provided in Senate Bill 1. Thank you!
- 2. 5% COLA per year for Exempt Salaries, especially for the Chief Scientific Officer



Cancer Prevention & Research Institute of Texas Chief Scientific Officer position requires skill set of high-level health science center MD/PhD research administrator (medical school dean, comprehensive cancer center director, cancer research division head)

- Request 5% COLA from \$608,850 to \$639,300 in FY 2024
- Request 5% COLA from \$639,300 to \$671,300 in FY 2025
- Comparable positions now average \$964,173





www.cprit.texas.gov

PO Box 12097 Austin Texas 78711 (512) 463-3190

Wayne R. Roberts Chief Executive Officer

Academic Research Program

Michelle Le Beau, Ph. D. Chief Scientific Officer

Product Development Research Program

Ken Smith, Ph. D. Chief Product Development Officer

Prevention Program

Ramona Magid Chief Prevention Officer

Strategic Initiatives

Tracey Davies Chief Strategic Initiatives & Intellectual Property Officer

Legal

Kristen Doyle Deputy Executive Officer & General Counsel

Operations

Heidi McConnell Chief Operating Officer

Compliance Vince Burgess Chief Compliance Officer

Communications Mark Dallas Loeffler Communications Director



2024-25 LAR: Appendix

CPRIT Background



Cancer Prevention & Research Institute of Texas In 2007, Texans voted overwhelmingly in favor of a constitutional amendment creating the Cancer Prevention and Research Institute of Texas (CPRIT).

On November 5, 2019, Texas voters approved a constitutional amendment providing an additional \$3 billion to CPRIT, for a total \$6 billion investment in cancer research and prevention efforts across Texas, the second largest public source of funding for cancer research in the world.




CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS Invest in the research prowess of Texas institutions.

Create and expand the life science infrastructure in Texas and add high-quality jobs.

Expedite innovation in research and breakthroughs in prevention and cures.

CPRIT's Unique Role in Fighting Cancer



Average R&D cost for approved drug: \$2 Billion

General timeframe to approved drug: 10-15 years



Investing in Research Prowess in Texas Research Entities

- 285 stellar researchers and their labs recruited to Texas institutions
- Texas achieves 3 NCI comprehensive cancer centers – previously only MD Anderson
- \$2.27 billion in 1,483 grants awarded to Texas research entities

- \$3.25 billion in direct follow-on funding raised by CPRIT academic research grantees
- 73 core facilities at Texas institutions to provide access to cutting-edge shared technology

James Allison 2018 Nobel Prize in Physiology or Medicine





36 Research Entities Have Received CPRIT Research Grants

- Baylor College of Medicine
- Baylor Research
 Institute
- Baylor University
- Rice University
- Scott & White
 Healthcare
- Southern Methodist
 University
- Texas A&M Engineering Experiment Station
- Texas A&M University
- Texas A&M University
 Corpus Christi
- Texas A&M University System Health Science Center
- Texas A&M University



Cancer Prevention & Research Institute of Texas Health Science Center Institute of Biosciences and Technology

- Texas AgriLife Research
- Texas Medical Center Foundation
- Texas Southern
 University
- Texas State University
 San Marcos
- Texas Tech University
- Texas Tech University Health Sciences Center
- Texas Tech University Health Sciences Center at El Paso
- The Methodist Hospital Research Institute

- The University of Texas at Arlington
- The University of Texas at Austin
- The University of Texas at Dallas
- The University of Texas at El Paso
- The University of Texas at San Antonio
- The University of Texas Health Science Center at Houston
- The University of Texas Health Science Center at San Antonio
- The University of Texas Health Science Center at Tyler
- The University of Texas M.D. Anderson

Cancer Center

- The University of Texas Medical Branch at Galveston
- The University of Texas Southwestern Medical Center
- The University of Texas Rio Grande Valley
- The University of Texas System
- University of Houston
- University of Houston
 Downtown
- University of North Texas
- University of North Texas Health Science Center at Fort Worth

Accelerating Innovation in Research


251 CPRIT-funded Clinical Studies: 41,371 Patients

- Interventional
 - 148 studies
 - 10,853 patients
- > Observational
 - 81 studies [[]]
 - 30,518 patients





Product Development Companies by City



INSTITUTE OF TEXAS

Create and Expand Life Science Infrastructure

Follow-on funds raised by academic research grantees and CPRIT-funded companies exceed contracted awards by \$ 5.55 Billion

\$8.40 Billion

Total Non-State Followon Funding

\$2.85 Billion


CPRIT Contracts to Academic Research and CPRIT-funded Companies



CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS

Prevention Program Services & Geographic Coverage

COUNTIES OF RESIDENCE OF PEOPLE SERVED BY CPRIT PREVENTION PROJECTS



CPRIT has funded \$328 million for 274 prevention projects at 56 Texas organizations

Over 8.2 Million Education and Clinical Services

- 4.7 M Education & Training Services
- 3.5 M Clinical Services
 - ✓ Vaccinations
 - ✓ Tobacco Cessation
 - Screening: breast, cervical, colorectal
 - ✓ Genetic testing and counseling
 - ✓ Survivor care



CPRIT: Investing in a Cancer-Fighting Ecosystem

\$3.18 Billion Invested as of November 2022

Investment	Direct Return in FY 2022	Value
All Program Investments	 7,840 jobs in annual employment \$436.8 million in personal income \$1.2 billion in total expenditures \$165.8 million in retail sales \$49.4 million in state and local tax receipts \$630.1 million in gross product 	 CPRIT is catalyzing the Texas life sciences ecosystem directly and thru the entire cancer healthcare continuum. If Texas achieves a concentration in the biomedical industry by 2050 equivalent to that of the US, incremental gains will include \$22.4 billion in annual gross product and 166,503 jobs.

